Sino Biopharm Shares Sink 14% in Hong Kong After Earnings Shock

Chinese drugmaker Sino Biopharmaceutical Ltd. plunged by as much as 14% in Hong Kong after its third-quarter earnings missed expectations, partly due to the impact of a centralized drug procurement program on prices.